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Pheochromocytoma: how to diagnose it? 
Prof. Dr. Claudia Reusch, DiplECVIM-CA 
Clinic for Small Animal Internal Medicine, University of Zurich 
Switzerland 
 
Pheochromocytomas are catecholamine-producing neuroendocrine tumors arising from 
chromaffin cells of the adrenal medulla. Pheochromocytomas are potentially malignant and 
local invasion into the adjacent vessels and other tissues is seen in more than 50% of dogs, 
sites of metastasis are regional lymph nodes, spleen, liver, kidney, pancreas, lung, heart, bone 
and CNS. The tumors are usually slow growing. Size is extremely variable and ranges 
between a few millimeters and more than 10 cm in diameter. 
Most tumors are unilateral, occasionally both adrenal glands are affected. They may coexist 
with cortisol-producing adrenocortical tumors, ACTH-producing pituitary tumors or other 
endocrine tumors.  
Clinical signs are usually the result of catecholamine excess and/or rarely from the space-
occupying or invasive nature of the tumor. Catecholamines bind to α- and β-adrenergic 
receptors and induce “fright, fight and flight” reactions. Important effects are: increase of 
heart rate and contractility, increase of blood pressure and respiration rate, relaxation of 
gastrointestinal tract and urinary bladder, increase of blood glucose and free fatty acids and 
increased alertness. In healthy dogs the content of the adrenal medulla is approximately 30% 
norepinephrine and 70% epinephrine. In dogs with pheochromocytoma, the proportion of the 
hormones may be different from healthy dogs and norepinephrine may be the predominant 
secretory product. Hormone secretion may be constant or sporadic and is highly 
unpredictable. The disease may occur at any age, however, it is most commonly seen in older 
dogs. There are no apparent sex and breed predispositions. The clinical presentation is highly 
variable. Signs may be apparent several times per day or may only reoccur after days, weeks 
or months. Severity of the disease ranges from dramatic and life-threatening to very mild. 
Some pheochromocytomas are hormonally silent.  
Clinical signs may be categorized as:  
1. non-specific: anorexia, weight loss, lethargy 
2. related to the cardio-respiratory system and/or hypertension: tachypnoe, panting, 
tachycardia, arrhythmias, collapse, pale mucous membranes, nasal-, gingival-, ocular 
hemorrhage, acute blindness due to retina detachment 
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3. related to the neuromuscular system: weakness, anxiety, pacing, muscle tremor, seizures 
4. miscellaneous: polyuria/polydipsia, vomiting, diarrhoe, painful abdomen.  
The most common signs are weakness and episodic collapse. Large tumors may cause 
abdominal distension, ascites and hind-limb edema. Intra-abdominal or retroperitoneal 
hemorrhage due to tumor rupture is also possible.  
Hypertension is one of the hallmarks of the disease. However, hypertension is not 
pathognomonic for pheochromocytoma and is also frequently found in hyperadrenocorticism, 
which is one of the most important differential diagnosis. 
Due to the episodic secretion of catecholamines, hypertension is only present in 
approximately 50% of dogs by the time of examination. Typically, systolic measurements are 
between 200 and 240 mm Hg, the maximum systolic blood pressure reported so far was 325 
mm Hg. 
Often pheochromocytoma is only considered after an adrenal mass has been detected by 
ultrasonography. No pattern of echogenicity or architecture is specific for 
pheochromocytomas, other adrenal masses e.g. cortisol-producing tumors may look alike.  
CT and MRI  are more sensitive than ultrasonography to identify adrenal masses and to 
characterize the extent of local invasion, however, they also do not allow a discrimination 
between pheochromocytoma and other adrenal masses. 
In humans, diagnosis of pheochromocytoma is mainly based on biochemical detection of 
excessive amounts of catecholamines (epinephrine, norepinephrine) and their metabolites 
(metanephrine, normetanephrine) in 24-h urine or in plasma. Although the question which test 
(urine or plasma) is best, is still somewhat controversial, plasma metanephrines tended to be 
recommended increasingly as test of choice. In dogs, evaluation of those biomarkers for the 
diagnosis of pheochromocytoma has started only a few years ago. Since 24-hours urine 
sampling is impracticable under clinical conditions, measurements of urinary fractionated 
catecholamines and metanephrines was established in spot urine samples by expressing their 
concentrations as ratio to the urinary creatinine concentration. Urinary normetanephrine to 
creatinine ratio was shown to be the parameter, which differentiated dogs with 
pheochromocytoma best from healthy dogs and dogs with hypercortisolism. We are currently 
using a cut-off value of urinary normetanephrine:creatinine ratio of 4 times of normal as being 
diagnostic for pheochromocytoma. However, lower values do not exclude the disease and 
repetitive testing may therefore be required. Sample collection and urine processing are 
subject to certain conditions, such as acidification, light protection, cooled or frozen storage. 
Close collaboration with the laboratory is therefore necessary.  
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We recently compared the diagnostic performance of urinary and plasma catecholamines and 
metanephrines by evaluating healthy dogs and dogs with pheochromocytoma, 
hypercortisolism  or non-adrenal disease. Discrimination of dogs with pheochromocytoma 
was superior with urinary and plasma normetanephrine compared to urinary and plasma 
metanephrine. The differences between the urinary and the plasma tests were, however, small. 
In conclusion, measurement of normetanephrine is the preferred biochemical test for 
pheochromocytoma. As differences between the urine and plasma test are minor, decision 
between both tests should be made based on available technical facilities and dog-specific 
reference ranges. 
Adrenalectomy is the treatment of choice and should be performed as soon as possible. It has 
been shown that perioperative mortality decreases if dogs are pretreated with an α-adrenergic 
blocker (phenoxybenzamine) for at least 1 - 2 weeks before surgery. In dogs surviving the 
perioperative period, survival for several years is possible.  
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